GCM
BBIO icon

Graham Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Graham Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-698,900
Closed -$19.2M – 1294
2024
Q4 		$19.2M Buy
698,900
+17,600
+3% +$455K 0.29% 34
2024
Q3 		$17.3M Buy
681,300
+294,200
+76% +$7.72M 0.3% 43
2024
Q2 		$9.81M Hold
387,100
– – 0.21% 56
2024
Q1 		$12M Hold
387,100
– – 0.23% 62
2023
Q4 		$15.6M Buy
+387,100
New +$11.6M 0.35% 44

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's BBIO Position: Q1 2026 in Review

Graham Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 101,051 shares — an estimated $7.73M sold.

Graham Capital Management first reported a position in BBIO in Q1 2022 and held it in 10 quarters. The position peaked at $14.4M in Q3 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Graham Capital Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 101,051 BridgeBio Pharma shares in Q1 2026, an estimated $7.73M.
  • Graham Capital Management first reported a position in BridgeBio Pharma in Q1 2022 and held it in 10 quarters.
  • Graham Capital Management's BridgeBio Pharma position peaked at $14.4M in Q3 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.